Cannvas MedTech (CSE:MTEC), a leader in digital cannabis education and a leading business technology company in the cannabis space, is pleased to announce the inception of its Cannvas Health Advocacy Team (CHAT) to delve deeper into health conditions and provide clarity on lesser-known medical ailments affecting large swaths of the population. Each CHAT module will focus on a particular illness, with a breakdown of its history, symptoms and potential treatments alongside patient and caregiver stories, doctor discussion guides and additional resources.

The first CHAT project, in partnership with Pancreatic Cancer Canada to mark National Pancreatic Cancer Awareness Month in November, is online at Cannvas.Me/PancreaticCancer with more to be announced shortly.


“The Cannvas Health Advocacy Team plays a crucial role on the Cannvas.Me platform, delivering a richer understanding of complicated ailments in simple terms anyone can understand, highlighting critical illnesses and conditions alongside potential alternative treatments and real-life patient and caregiver stories,” said Steve Loutskou, Chief Operating Officer, Global Markets at Cannvas MedTech. “It made sense to debut our first CHAT module to coincide with National Pancreatic Cancer Awareness Month to shed more light on a terrible disease with low survival rates and little public awareness that has personally affected the loved ones of several of our Cannvas employees, and we hope to continue educating our community about serious medical issues that could affect them or their loved ones.”

Made up of members of the Cannvas.Me Medical Advisory Board and Educational Advisory Panel, the Cannvas Health Advocacy Team aligns original educational Cannvas.Me content with expert medical advice from strategic partners in the healthcare, education, public safety and health advocacy sectors. With support from certified medical practitioners and sanctioned non-profit organizations, CHAT aims to break down an illness by laying out its history, cultural impact, symptoms and treatments in simple and accessible terms; provide supporting resources such as discussion guides for families and doctors; and share information on the potential benefits of cannabis as an alternative or supporting treatment where appropriate.

“Our goal with the Cannvas Health Advocacy Team is to give a voice to all those patients and caregivers navigating the challenges of unexpected and unfamiliar illnesses with little support, and provide them with another community from which to learn about their options and hear from others who have gone through similar experiences,” said Shawn Moniz, Chief Executive Officer at Cannvas MedTech. “By tapping into our internal team of health practitioners and certified educators, coupled with the resources provided by our partner organizations, CHAT provides free and unbiased educational content around medical conditions needing more clarity among everyday Canadians.”

By gathering and sharing user-submitted patient and caregiver stories pertaining to the illness profiled, the Cannvas Health Advocacy Team hopes to engage the Cannvas community to share their experiences, support systems and alternative or supporting therapies including but not limited to the use of cannabis. Working with healthcare practitioners and educators holding specializations in their fields strengthens the unbiased information available in CHAT modules to Cannvas.Me users and sheds more light on a litany of diseases with low public awareness.

Cannvas will also look to continue to form strategic partnerships with regional and national health-focused non-profit advocacy groups to strengthen its pool of resources for CHAT and the Cannvas.Me platform.

About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

For further information: www.cannvasmedtech.com; Media Inquiries: media@cannvasmedtech.com; Investor Relations, ir@cannvasmedtech.com, 1-800-489-0116

Related Links

https://cannvasmedtech.com

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 

Source: www.newswire.ca

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less